Toll-like receptor 9 (TLR9) recognizes microbial DNA. We show here that TLR9 protein is expressed in human breast cancer cells and clinical breast cancer samples. Stimulation of TLR9-expressing breast cancer cells with the TLR9 agonistic CpG oligonucleotides (1-10 Mmol/L) dramatically increased their in vitro invasion in both Matrigel assays and three-dimensional collagen cultures. Similar effects on invasion were seen in TLR9-expressing astrocytoma and glioblastoma cells and in the immortalized human breast epithelial cell line MCF-10A. This effect was not, however, dependent on the CpG content of the TLR9 ligands because the non-CpG oligonucleotides induced invasion of TLR9-expressing cells. CpG or non-CpG oligonucleotide-induced invasion in MDA-MB-231 cells was blunted by chloroquine and they did not induce invasion of TLR9 À breast cancer cells.
Introduction
Toll-like receptors (TLR) are evolutionarily well-conserved transmembrane proteins that are present in almost all multicellular organisms and recognize patterns specific of microbial components (1, 2) . In mammals, the TLR family is currently known to consist of 11 members, which exhibit specificity for pathogen-derived ligands. For example, TLR4 recognizes the bacterial lipopolysaccharide, whereas members of the TLR9 subfamily (TLR7-TLR9) sense the microbial RNA and DNA (1, 2) . Oligonucleotides with unmethylated CpG dinucleotides mimic the immunostimulatory activity of bacterial DNA in vertebrates and are also recognized by TLR9 (3) (4) (5) (6) .
TLR1, TLR2, and TLR4 are expressed on the cell surface, whereas TLR3 and members of the TLR9 subfamily are intracellular (7) (8) (9) (10) . More specifically, TLR9 is localized to endoplasmic reticulum, from where it is translocated to the endosomal/lysosomal compartment for ligand recognition (10) . On ligand binding, the various TLRs and their associated adapters, such as MyD88 and TRIF, recruit intracellular signaling mediators that activate transcription factors, such as nuclear factor-nB. The outcome of TLR activation is an immune reaction characterized by increased production of various proinflammatory cytokines and interleukins (2) .
In humans, TLR9 is most abundantly expressed in plasmocytoid dendritic cells and B cells, whereas in mice myeloid dendritic cells as well as macrophages and B cells also express TLR9 (2) . Interestingly, several epithelial cell types and astrocytes have also recently been reported to express various TLRs, implying that also other cells than the actual immune cells may be important sentinels of the innate immune system (9, (11) (12) (13) (14) (15) . High expression of TLR9 was recently detected in clinical samples of lung cancer and in lung cancer cell lines. In these cells, stimulation of TLR9 with its agonists was shown to result in cytokine production (16) . Responsiveness of breast cancer cells to TLR ligands and the presence of TLRs in breast milk suggest that these receptors are also expressed in breast epithelial cells (17, 18) .
The aim of this study was to further characterize TLR expression and function in human breast cancer cells. Because the original observation concerning the role of Toll in Drosophila was that it mediates dorsoventral patterning, we hypothesized that TLRs may mediate similar functions also in cancer cells (19, 20) .
Results

TLR9 Is Expressed in Breast Cancer Cell Lines and Clinical Samples of Breast Cancer
MDA-MB-231 cells express relatively high levels of mRNA for TLR4 and TLR9 but only very little or no mRNA for the other TLR1 to TLR10 as detected in DNA arrays (Fig. 1A) . Breast cancer cell responsiveness to lipopolysaccharide, a ligand for TLR4, has been described previously, suggesting that functional TLR4 can be expressed in breast cancer cells (18) . Therefore, in this study, we decided to focus on TLR9 expression and function. Flow cytometry as well as immunohistochemistry of the permeabilized MDA-MB-231 cells suggested intracellular expression of TLR9 as also shown previously in other cells ( Fig. 1B and C (Fig. 1D ). TLR9 expression was also detected with Western blot in normal mammary gland tissue and in three of five malignant breast tumors. Interestingly, the TLR9 band detected in the normal mammary gland tissue appeared slightly heavier than the TLR9 band in the malignant tumors and in the MDA-MB-231 cells (Fig. 2A) . The same blot was stripped and reblotted with anti-CD45 antibody, which is a pan-leukocyte marker (22) . No specific expression of CD45 was seen, suggesting that the TLR9 expression in these lysates is likely from the epithelial cells of the breast (data not shown). TLR9 expression was also detected in immortalized human breast epithelial cell line MCF-10A (Fig. 2B) . Taken together, these results suggested that TLR9 is relatively frequently expressed in both normal and cancerous mammary epithelial cells.
TLR9 Agonists Induce Invasion in TLR9-Expressing Cancer Cells
To study the effects of TLR9 stimulation on breast cancer behavior, we did invasion and cell viability assays using the well-characterized TLR9 agonists, CpG motif containing unmethylated oligonucleotides (CpG oligonucleotide), which mimic the actions of bacterial DNA (2) . Three different CpG oligonucleotides (types A-C), with slight variations in their sequences, were tested. Types B and C represent CpG oligonucleotides with the conventional nuclease-resistant phosphorothioate backbone, and type A carries a combination of phosphorothioate and phosphodiester modifications. It has been shown previously that such modifications result in a slightly different cytokine responses from dendritic cells at 0.01 to 10 Amol/L concentrations (23) . All these CpG oligonucleotides induced a dose-dependent increase in the number of MDA-MB-231 cells that invaded through Matrigel. The treatment-induced increased invasion ranged from 2-to 10-fold and was statistically significant even with the lowest (1 Amol/L) concentrations tested. Surprisingly, the non-CpG oligonucleotides, which are considered unstimulatory controls for the TLR9 agonistic CpG oligonucleotides, induced invasion of MDA-MB-231 cells to a similar level. The type C CpG oligonucleotide was chosen for further studies, because it is a combination of types A and B CpG oligonucleotides and because it induced, along with the type B CpG oligonucleotides, the highest dose responsiveness (Fig. 3A and B) . Similar effects on invasion were also seen when MDA-MB-231 cells were cultured for 7 days in the presence of 10 Amol/L type C CpG oligonucleotides in three-dimensional collagen culture assays ( Fig. 3C and D) . The type C CpG oligonucleotides (10 Amol/L) stimulated invasion also in the unrelated, strongly TLR9-expressing U373 astrocytoma and D54MG glioblastoma cells and in T47-D breast cancer cells (Fig. 3E and F) . Treatment with the type C CpG oligonucleotides or with the type C non-CpG oligonucleotides (1 and 10 Amol/L, data not shown for 1 Amol/L) stimulated invasion also in the immortalized mammary epithelial cell line MCF-10A, but they did not, however, stimulate invasion in the TLR9 À MCF-7 breast cancer cells ( Fig. 3E and G) . The increased cell numbers seen in the invasion assays were not due to an effect on proliferation or apoptosis, because the type C CpG oligonucleotide (10 Amol/L) had no effect on cell viability during an incubation of 24 hours (Fig. 4) . During longer incubation (after 3 and 6 days), both type C non-CpG oligonucleotide and type C CpG oligonucleotide actually significantly decreased viability as detected with 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt assays (Table 1 ). Taken together, these studies suggested to us that TLR9 agonists stimulate invasion in TLR9 + but not in TLR9 À cancer cells. To further study the role of TLR9 in mediating invasion, we did the invasion assays with and without chloroquine, an inhibitor of endosomal maturation, which has been shown to prevent TLR9 signaling in other cells (24) . As shown in Fig. 5 , addition of chloroquine (10 Amol/L) inhibited both CpG and non-CpG oligonucleotide-induced invasion. Similar results were obtained also with higher chloroquine doses (25 Amol/L; data not shown), but because they compromised cell viability, they were not routinely used.
TLR9 Agonists Induce Matrix Metalloproteinase Activity
To investigate the mechanism behind the TLR9 agonistinduced invasion, we did gelatin-zymogram assays. Supernatants from MDA-MB-231 cells that were treated with 5 or 10 Amol/L type C CpG oligonucleotides or for 24 hours induced the formation of a gelatinolytic band of f50 kDa. The appearance of this band was not inhibited with the serine protease inhibitor aprotinin, but it did disappear when the gels were incubated with the broad-spectrum matrix metalloproteinase (MMP) inhibitor GM6001. The size of the band was similar to that induced by a positive MMP-13 control sample (Fig. 6A) . Similar results were obtained with the type C nonCpG oligonucleotide (data not shown). Consistent with these findings, the type C CpG-induced invasion of MDA-MB-231 cells was also inhibited by the MMP inhibitor but not by the serine protease inhibitor aprotinin in Matrigel assays (Fig. 6B ). (Fig. 7C ). Specific inhibitor of MMP-8 inhibited basal invasion (mean F SD number of invaded cells, 50 F 9 versus 17F 3, basal versus MMP-8 inhibitor, respectively; P < 0.05), but it did not block CpG oligonucleotide-induced invasion (Fig. 7D ). Taken together, these findings suggested to us that CpG oligonucleotide (and non-CpG oligonucleotide) -induced invasion is mediated via MMP-13. Type C CpG oligonucleotide treatment did not, however, increase MMP-13 expression, suggesting that these TLR9 agonists stimulate breast cancer invasion via activating MMP-13 ( Fig. 8A ). The TLR9 agonist did not affect the expression of plasminogen activator inhibitor-1, plasminogen activator inhibitor-2, or tissue inhibitor of metalloproteinase (TIMP)-1, which can regulate urokinase-type plasminogen activator -and MMPmediated invasion either (data not shown; refs. 26, 27) . We did, however, find differences in the expression levels of TIMP-3, which can inhibit MMP-13 activity (28) . Treatment with the type C CpG oligonucleotide decreased the expression of TIMP-3 in the cell lysates of TLR9 + MDA-MB-231 and T47-D cells but not in the TLR9
À MCF-7 cells (Fig. 8B ). High levels of TIMP-3, which were not affected by the CpG oligonucleotide treatment, were detected only in the supernatants of the MCF-7 cells.
Discussion
Environmental and epigenetic factors, such as infections and resulting inflammation, are important regulators of tumor progression (29) . The innate immune system can promote tumor development and progression through inflammationdependent mechanisms (29, 30) . For example, chemokines and cytokines derived from the immune and inflammatory cells can dramatically affect the host microenvironment and cancer cell behavior, resulting in increased growth and metastasis. Mediators of the innate immunity may also modulate the invasive capacity of cancer cells directly. Endotoxin/lipopolysaccharide, a cell wall constituent of Gram-negative bacteria, has been shown to promote metastasis in a mouse model of colon cancer (31, 32) . In addition to the cytokine-mediated indirect effects on tumor progression, lipopolysaccharideinduced effects on metastasis may also be mediated via direct, increased invasiveness of the cancer cells, which frequently express TLRs (32).
We describe here a novel, direct mechanism through which TLR9, a cellular receptor for microbial DNA, may enhance cancer invasiveness. The effects were seen already with 1 Amol/L CpG oligonucleotide, a concentration that induces peak activation of innate immunity in many cellular systems (33) (34) (35) . Although we used breast cancer cells as a model system, our results imply that a similar mechanism can also be seen in other TLR9-expressing cancers, for example, in brain cancer cells. The fact that expression of TLR9 has also been reported in lung and gastric cancer cells suggests that TLR9-mediated increased invasion may be a general feature in cancer cells that are exposed to infectious agents (9, 15, 16) . It was indeed shown recently that also Helicobacter pylori induces invasion of gastric cells through TLR2/TLR9-mediated induction of cyclooxygenase-2 (36). The CpG oligonucleotideinduced invasion is not, however, limited to cancer cells alone because we saw similar effects also in the immortalized breast epithelial cell line MCF-10A. In Drosophila, Toll was originally identified as a transmembrane receptor required for the establishment of dorsoventral polarity in the developing embryo (20) . It was also found to be important in Drosophila immunity, as flies lacking this protein were highly susceptible to infection with Aspergillus fumigatus (37). Therefore, it seems that both these functions of Toll, the ability to recognize and fight against infectious microorganisms and the ability to mediate invasion, seem evolutionarily well conserved between Drosophila and mammalian epithelial cells.
Our findings further suggest that TLR9 agonists stimulate breast cancer invasion via activating MMP-13 but not MMP-8. However, contributions from other MMP family members cannot be ruled out. These findings are in line with the recent reports that showed that in breast cancer cells MMP-8 may actually exert inhibitory effects on invasion (38) . The TLR9 agonists did not affect the expression of plasminogen activator inhibitor-1, plasminogen activator inhibitor-2, or TIMP-1, which regulate urokinase-type plasminogen activator -and MMP-mediated invasion either (data not shown; refs. 26, 27). We did, however, discover differences in the expression of TIMP-3, which has been shown to inhibit MMP activity, including MMP-13 (28) . CpG oligonucleotide treatment decreased the expression of TIMP-3 in the TLR9 + MDA-MB-231 and T47-D cells but not in the TLR9
À MCF-7 cells. The most prominent effect was seen on the expression of unglycosylated TIMP-3, which has been shown to exhibit similar MMP inhibitory activity than the glycosylated form (39, 40) . Interestingly, high levels of TIMP-3 were detected only in the supernatants of the MCF-7 cells, which are poorly invasive. This is surprising in the light that TIMP-3, once secreted, is typically associated with the insoluble extracellular matrix (39, 41) . The reason for this increased localization of TIMP-3 in the MCF-7 supernatants is currently not known, but it may be related to slight differences in protein glycosylation (39) . Although the TIMP-3 levels were unaffected by the CpG oligonucleotide treatment in the MCF-7 supernatants, the high constitutive expression of TIMP-3 may partially explain the very low invasive capacity of these cells in general. Taken together, these findings are consistent with our previous report where we showed that increased TIMP-3 expression is associated with decreased invasion in the human MDA-MB-231 breast cancer cells (42) . It was also shown previously that treatment of mouse astrocytes with CpG oligonucleotides resulted in increased expression of MMP-9 (4). Therefore, TLR9 agonist-induced MMP profile may be cell specific. Alternatively, the effect in astrocytes may also MMP-13 mediated, because MMP-13 has been shown to activate pro-MMP-9 (43). It was shown recently that not all CpG oligonucleotideinduced responses are, however, TLR9 mediated. For example, CpG motif containing DNA activated the Akt pathway and this was dependent on the DNA-dependent protein kinase but not on TLR9 (44) . Furthermore, plasmid DNA containing CpG motifs elicited similar immune responses in TLR9
À/À and in TLR9 +/+ mice (45) . On the other hand, non-CpG oligonucleotides especially in the phosphorothioate backbone induced chemokine induction on the CD14 + sorted, TLR9 À monocytes, but they did not activate TLR9-transfected cells (34) . NonCpG-containing antisense oligonucleotides activated a proinflammatory response also in TLR9-deficient mice (46) . The fact that we saw increased invasion by CpG or non-CpG oligonucleotides and increased MMP-13 activity levels by CpG oligonucleotides only in TLR9-expressing cancer cells but not in TLR9 À cells and the fact that the invasion effects of these oligonucleotides were blunted by chloroquine, however, strongly argue that these effects on invasion are mediated via TLR9. This conclusion is supported by a recent report that showed that TLR9 mediates also the effects of non-CpG oligonucleotides, especially if they are phosphorothioate modified (33) . Our data, however, imply that TLR9 expression level per se does not correlate with the invasive response to CpG oligonucleotide treatment. This suggest that downstream signaling molecules of the TLR9 pathway may be important regulators of this response. Furthermore, our results suggest that the TLR9 isoform expressed by cancer cells may be different from that expressed in normal mammary epithelial cells. These observations need to be confirmed with further studies. Our finding has several important implications. First, they may give novel clues to why certain infections; for example, Mycoplasma might promote cancer progression (47) . Mycoplasma infections have been detected in various cancers, including breast cancer (48, 49) . After having been taken up by the cells, Mycoplasma bacteria have been detected in the same subcellular localization, the lysosome, where also activated TLR9 is localized (21, 50) . The identical subcellular location of TLR9 and Mycoplasma at least in theory facilitates the possibility that binding of Mycoplasma DNA to the cellular TLR9 could result in increased invasion. Second, CpG oligonucleotides are being tested in preclinical models as adjuvants for cancer immunotherapy (51) . Although the concentrations of CpGs that have been used to treat mice in the various murine tumor models, where these compounds were shown to have anticancer efficacy possibly through dendritic cell activation, are much lower than the doses used here, our findings warrant caution in the use of immunomodulatory TLR9 agonists in the treatment of cancer and suggest screening of TLR9 expression of the tumors (52, 53) . Finally, a recent study revealed a connection between an increased risk for the development of prostate cancer and a sequence variant of TLR4 (54) . It is thus possible that similar sequence variations in the TLR9 gene might also explain the individual's susceptibility to cancer progression.
Materials and Methods
Chemicals
Phosphorothioate-modified, human-specific CpG oligonucleotides [type A: 5 ¶-ggGGGACGATCGTCgggggg-3 ¶, in which only the bases that are shown in capital letters are phosphodiester, and those in lower case are phosphorothioate (nuclease resistant), type B: 5 ¶-tcgtcgttttgtcgttttgtcgtt-3 ¶, type C: 5 ¶-tcgtcgtcgttcgaacgacgttgat-3 ¶] and their non-CpG oligonucleotide controls (type A-control: 5 ¶-ggGGGAGCATGCTGgggggc-3 ¶, type B-control: 5 ¶-tgctgcttttgtgcttttgtgctt-3 ¶, type C-control: 5 ¶-tgctgctgcttgcaagcagcttgat-3 ¶) were purchased from Invivogen (San Diego, CA) and dissolved into endotoxin-free sterile distilled H 2 O per manufacturer's suggestion and used at the indicated concentrations. Matrigels were from BD Biosciences (Bedford, MA), serine protease inhibitor aprotinin and MMP inhibitor GM6001 were from EMD Biosciences (La Jolla, CA), MMP-8-specific inhibitor I and the negative control compound were from Calbiochem (San Diego, CA), and MMP-13 immunoblotting standard (human) for the zymography was from Biomol (Plymouth Meeting, PA).
Cell Culture
Human MDA-MB-231 breast cancer, U373 astrocytoma, and D54MG glioblastoma cells were cultured in DMEM (Life Technologies, Paisley, United Kingdom) supplemented with 10% heat-inactivated fetal bovine serum, L-glutamine, penicillin/streptomycin, and nonessential amino acids (all from Life Technologies). T47-D cells were cultured in RPMI, and MCF-7 cells were cultured in a-MEM, supplemented with 10% heatinactivated FCS, 100 units/mL penicillin, 100 Ag/mL streptomycin, and 2 mmol/L glutamine and with 10 Ag/mL insulin (Sigma, St. Louis, MO). MCF-10A cells were cultured as described previously in detail (55) . All cell cultures were done in incubators in a 37jC atmosphere of 5% CO 2 /95% air.
TLR mRNA Expression Profiling
The mRNA expression levels of the various TLRs in MDA-MB-231 cells was investigated using the SuperArray human TLR pathway-specific gene expression profiling system (SuperArray Bioscience Corp., Frederick, MD). Briefly, total cellular RNA was isolated using the RNAzol reagent (Tel-Test, Inc., Friendswood, TX) from the cells grown in normal culture medium and converted to a labeled cDNA probe. The denatured cDNA was hybridized overnight at 60jC to nylon membrane that contained the target cDNAs. Chemiluminescence was used to detect the hybridization signal on a X-ray film (Eastman Kodak Co., Rochester, NY). Per manufacturer's instructions, the X-ray film was scanned with a high-resolution scanner (f300 dpi) into a JPEG-format image and converted into a TIFF format (8-bit inverted grayscale) image by using a Photoshop software (Adobe Systems, Inc., San Jose, CA). The images were then uploaded into a software ScanAlyze (Eisen Lab, University of California at Berkeley) to produce a raw intensity data sheet.
The raw data from both the control and the treated groups were combined and uploaded into a software GEarray Analyzer (SuperArray, Inc., Bethesda, MD), where differences and ratios between the treated and the control groups were analyzed. Background was subtracted from signals and a housekeeping gene, such as actin, was used to calculate the ratio.
Flow Cytometry
MDA-MB-231 cells were cultured on Petri dish (Ø 15 cm) until f70% confluent. The cells were then detached using CellStripper (Fisher Scientific, Hampton, NH) and prepared for analysis using the BD Cytofix/Cytoperm kit (BD Biosciences, San Diego, CA) according to the manufacturer's recommendations. Briefly, f1 Â 10 6 cells were suspended into 0.5 mL of the fixative solution. After washing the cells twice, phycoerythrinconjugated anti-human TLR9 antibody (eBioscience, San Diego, CA) or phycoerythrin-conjugated, isotype-controlled IgG was added to the cells (7 AL/tube). After incubation for 30 minutes at 4jC, the cells were rinsed twice with PBS and analyzed with fluorescence-activated cell sorting.
Immunohistochemistry
For the immunohistochemical stainings, the MDA-MB-231 cells were grown on glass coverslips in normal culture medium. The cells were fixed with 3% paraformaldehyde-PBS for 10 minutes at room temperature, after which they were permeabilized with 0.025% saponin for 30 minutes on ice. After blocking the samples with 10% goat serum, staining with mouse monoclonal antibody to TLR9 (Abcam, Inc., Cambridge, MA) was done. Horseradish peroxidase -conjugated anti-mouse antibody was used to visualize the staining. The samples were then examined using a Leica (Bannockburn, IL) light microscope.
Western Blotting
The cells were cultured on six-well plates in their normal culture medium until near confluency, after which they were rinsed with sterile PBS and cultured for further 24 hours in serum-free culture medium. The culture medium was then Binding of the primary antibodies to the target proteins on the membranes was revealed with species-specific horseradish peroxidase -conjugated secondary antibodies (Cell Signaling). The same blots were stripped and reblotted, using anti-actin antibody (Sigma), to show equal loading. The protein bands were visualized by chemiluminescence using SuperSignal West Pico Enhanced Chemiluminescence kit (Pierce, Rockford, IL). Expression of TLR9 in human breast cancer specimens or normal breast tissue was studied from specimens that were obtained from the University of Alabama at Birmingham tissue repository. Briefly, the tissues were homogenized in the lysis buffer and analyzed with Western blotting as described above. The use of these samples for this purpose was accepted by the local institutional review board.
In vitro Invasion Assays
For the Matrigel invasion assay, the cells were plated at the density of 5 Â 10 4 (MDA-MB-231, U373, and D54MG), 15 Â 10 4 (T47-D), or 30 Â 10 4 (MCF-7) per upper well in 750 AL normal culture medium (56) . Indicated concentrations of the various CpG oligonucleotides, non-CpG oligonucleotides, or vehicle were added to both upper and lower wells. When indicated, aprotinin (2 Amol/L), GM6001 (2 Amol/L), MMP-8 inhibitor I (8 nmol/L), or the same volume of the corresponding control compound, control IgG or neutralizing anti-MMP-13 antibody (R&D Systems; both at 12 Ag/mL) or chloroquine (10 Amol/L) were also added to both upper and lower wells. The cells were allowed to invade for 18 hours, after which the inserts were removed and stained with the Hema 3 Stain set (Fisher Diagnostics, Middletown, PA) according to the manufacturer's recommendation. The number of invaded cells were counted from five preselected microscopic fields using a Â40 objective. To assess invasion in a threedimensional type I collagen gel, acid-solubilized type I collagen (0.9 ml) was added to the Costar Transwell dishes (Corning, Inc., Corning, NY) and gelled over 45 minutes at 37jC. The collagen was prepared using rat tail type I collagen dissolved in 0.2% acetic acid at 3.2 mg/mL and gelled by neutralizing the acid with 0.3 N NaOH containing phenol red as a pH indicator. A final concentration of 3.0 mg/mL was obtained. Medium containing vehicle or 10 Amol/L type C CpG oligonucleotide was then added to the upper and lower chambers before the addition of 5 Â 10 5 cells to the surface of the collagen gel in the presence of serum-containing medium. Medium was changed every 3 days over the 7-day incubation period. Gels were then removed from the Transwell dish, fixed in 2.7% formaldehyde for 24 hours, and embedded in paraffin. Sections (6 Am) were cut and stained with H&E. Tumor cell invasion (depth and number of cells below the surface) was assessed by light microscopy in a minimum of four randomly selected sections for each experimental sample. The number of invading cells per high-power field (Â400) was counted and averaged. The depth of invasion was also measured in four randomly selected areas for each sample using photomicrograph of each sample.
Cell Viability Assays
MDA-MB-231, T47-D, or MCF-7 cells were plated at the density of 1,000 per well in 96-well plates in normal culture medium and cultured for the indicated periods of time with 10 Amol/L type C CpG oligonucleotide or vehicle. Cell viability was assessed after 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt was added for the final 2 hours of the experimental cultures as recommended by the manufacturer (CellTiter 96 AQ ueous Nonradioactive Cell Proliferation Assay, Promega, Madison, WI).
Zymograms
The zymograms were done as described previously (57) . In this assay, the gelatinolytic bands represent the following MMPs: 120-kDa band represents MMP-9 and neutrophil gelatinase-associated lipocalin complex, 90-kDa band represents pro-MMP-9, and the 72-kDa band represents pro-MMP-2 (58-60). Briefly, MDA-MB-231 cells were plated on 12-well plates and allowed to reach confluency. The cells were then rinsed with PBS and serum-free medium, with the indicated concentrations of type C CpG oligonucleotides, type C nonCpG oligonucleotides, or vehicle applied for 24 hours. The supernatants were then collected and a 35 AL aliquot was applied to zymograms (Novex 10% gelatin gels, Invitrogen, Carlsbad, CA) according to the manufacturer's suggestions. In further experiments, aprotinin (2 Amol/L) or GM6001 (2 Amol/L) was added to the final incubations of the gels to investigate whether CpG treatment induced serine protease or MMP activity.
MMP-13 ELISA
MDA-MB-231, T47-D, and MCF-7 cells were plated on 24-well plates at the density of 10 5 per well and allowed to reach confluency. The cells were then rinsed with PBS, and 200 AL serum-free medium, containing vehicle or 10 Amol/L type C CpG oligonucleotides, was added per well. The supernatants were collected 24 hours later and analyzed for levels of active MMP-13 with an ELISA that detects active MMP-13 (Calbiochem, La Jolla, CA) according to the manufacturer's instructions.
MMP-8 Analysis
The molecular forms and degree of activation of MMP-8 were analyzed by Western immunoblotting using anti-rabbit MMP-8 antibody (61) . After SDS-PAGE run under nonreducing conditions, the proteins on the gel were transferred onto a nitrocellulose filter (Bio-Rad Laboratories, Richmond, CA).
After blocking with 3% gelatin, the membrane first reacted with the primary antibody (1:500) and then with alkaline phosphatase -conjugated secondary antibody. Immunoreactive proteins were visualized by nitroblue tetrazolium (Sigma) and 5-bromo-4-chloro-3-indolyl-phosphate (Sigma). Quantitation was done with the Bio-Rad imaging densitometer using the Analyst program. Data are expressed as densitometric arbitrary units. Human neutrophil and rheumatoid synovial culture medium were used as positive controls for polymorphonuclear-type and mesenchymal-type MMP-8 isoforms, respectively (62) .
Statistical Analysis
Results are mean F SD unless otherwise stated. Student's t test was used to calculate statistically significant differences between the various study groups.
